Compare Kaltura Inc (KLTR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Organon & Co. Common Stock — how do they compare? Kaltura Inc trades at $1.38 (market cap $212.05M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 17.1× Kaltura Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Organon & Co. Common Stock for 0 Days on average.
| KLTR | OGN | |
|---|---|---|
Market Cap | $212.05M | $3.62B |
Volume | 264,699 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $1.89 | $13.81 |
52-Week Low | $1.08 | $5.70 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $224.26M | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLTR trades at $1.37, down 2.14% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported revenue of $180.85M in 2025, with a net loss of $12.07M, though losses have narrowed significantly from prior years. Recent news highlights include Gartner naming Kaltura a leader in AI for video platform services and a strategic partnership with Verimatrix for security.
The outlook remains speculative; while AI-driven growth and improving margins present upside potential, persistent losses, high valuation ratios, and negative cash flow pose substantial risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, but the stock's high volatility and weak profitability metrics warrant careful consideration.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
